Evidence Based Medicine

How are cell therapies redefining cancer care through rigorous HTA evaluation? INCA’s latest analysis highlights how CAR-T and other advanced cell therapies are shifting oncology paradigms—balancing innovation with evidence-based access and cost-effectiveness. Explore the full breakdown and its implications for global cancer treatment. #SyenzaNews #oncology #precisionmedicine #innovation #MarketAccess

What if blending ICU clinician models delivers the best patient outcomes? A new analysis comparing staffing approaches reveals that hybrid models—merging physician-led oversight with advanced practice provider expertise—outperform traditional structures in efficiency, cost, and care quality. Explore the full findings and see how this evidence can guide your ICU strategy. #SyenzaNews #healthcare #HealthcareInnovation #innovation #strategicplanning

Is Africa's HIV future at a crossroads? The Africa HIV Control Working Group's 2026 webinar spotlighted UNAIDS, UNICEF & health leaders on domestic financing, sovereignty, integrated systems & community leadership to build resilient HIV control. Read more & join the push for bold action. #HIVControl #AfricaHealth #BoldLeadership #UNAIDS #GlobalHealth

🤖 Can general-purpose LLMs truly outperform specialized clinical AI tools in real-world tests? Recent evaluations highlight where large language models excel—and where domain-specific tools still hold the edge—in accuracy, reliability, and clinical applicability. Explore the findings and their implications for healthcare AI adoption. #SyenzaNews #AIinHealthcare #HealthcareInnovation #ai #innovation

Could integrating pharmacogenomics into Africa’s essential medicines lists transform patient outcomes? 🧬🌍 This article outlines how using population-specific genetic data can reduce adverse drug reactions, optimize dosing, and improve therapeutic effectiveness—while highlighting the policy, capacity-building, and equity measures required for implementation. Read the full piece for practical recommendations and policy pathways to bring precision medicine into routine care across African health systems. #SyenzaNews #pharmaceuticals #precisionmedicine #healthcarepolicy #innovation

🔍 What's the latest from EMA's CHMP — and why should drug developers and market-access teams care? This roundup distills the CHMP meeting highlights into practical insights: key decisions, safety updates, and guidance that could affect approval timelines, clinical program strategies, and reimbursement planning. Read the full article for actionable takeaways to adapt your regulatory and market-access approach. #SyenzaNews #regulatoryaffairs #pharmaceuticals #MarketAccess #healthcarepolicy

How will the EU’s joint scientific consultation change the future of medical devices? 🔍🇪🇺 The article explains how coordinated scientific advice is bringing clearer evidence expectations, streamlined clinical evaluation, and stronger stakeholder engagement — all aimed at faster, safer market access for innovators and manufacturers. Read the full piece to learn what this means for your product strategy and regulatory planning. #SyenzaNews #medicaldevices #regulatoryaffairs #healthcarepolicy #innovation

Could Portugal's use of real‑world evidence transform HTA and speed patient access? 🔍🇵🇹 This article explains Portugal’s adaptive HTA pilots — how iterative decision frameworks, real‑world data and stakeholder‑aligned reimbursement models help manage uncertainty while enabling earlier access to innovative therapies. It draws out practical lessons for payers, manufacturers and policymakers aiming to modernize market access. Read the full piece to explore the enablers, pilot insights and implications for future HTA design. #SyenzaNews #HealthEconomics #regulatoryaffairs #MarketAccess #healthcarepolicy

Can gene therapy restore sight — and still fit into healthcare budgets? 👁️ This piece unpacks reimbursement pathways for vision-restoring gene therapies (e.g., RPE65/Luxturna), highlighting value assessment, long-term evidence needs, and practical payment models like outcomes-based agreements and annuities to manage uncertainty and budget impact. Read the full article to explore pragmatic strategies that payers, manufacturers, and clinicians can use to secure sustainable patient access. #SyenzaNews #biotechnology #HealthEconomics #MarketAccess #healthcarepolicy

Can policy reforms finally make insulin affordable for Medicare beneficiaries? 💊💸 This article reviews recent measures—such as the Medicare Part D insulin cap and state initiatives—assessing their effects on out‑of‑pocket costs, medication adherence, and health outcomes, while identifying implementation gaps and who still falls through the cracks. It maps the implications for patients, payers, and policymakers and outlines next steps to improve access. Read the full analysis to understand the real-world impact and what policy and industry stakeholders should prioritize next. #SyenzaNews #pharmaceuticals #HealthEconomics #healthcarepolicy #costeffectiveness

Can more precise cognitive measurement change how we forecast Parkinson’s progression? The article explores how sensitive cognitive tests, digital assessments and biomarker-informed models — powered by machine learning — can improve accuracy in predicting cognitive decline in Parkinson’s disease, with clear benefits for trial design and personalized care 🧠📈. Read the full piece to see the key methods, validation findings, and practical steps for adopting these tools in research and clinical settings. #SyenzaNews #digitalhealth #AIinHealthcare #ai #datascience

Who’s watching mifepristone’s safety data—and why it matters? 🔬⚖️ A recent safety study reconfirms mifepristone’s established safety profile but highlights gaps in post‑market surveillance and regulatory transparency. These findings could influence oversight practices, prescribing guidance, and access for patients. Read the full article for a clear breakdown of the data, regulatory implications, and what stakeholders should watch next. #SyenzaNews #regulatoryaffairs #pharmaceuticals #healthcarepolicy #governance